通过USP22/HIF-1α轴对PATZ1的抑制来缓解慢性心力衰竭
Yuntao Luo1, Fang Zhou1, Qingyang Chen2
1Department of Health Management, The First Hospital of Hunan, University of Chinese Medicine, Changsha, 410007, China.
Scientific reports
|November 18, 2025
概括
PATZ1/USP22/HIF-1α轴驱动慢性心力衰竭 (CHF) 的进展. USP22稳定了HIF-1α,而PATZ1提高了USP22的调节,恶化了心脏损伤. 针对这一轴提供了潜在的CHF疗法.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 慢性心力衰竭 (CHF) 的发病因子复杂且不完全理解.
- 缺氧诱导因子1-α (HIF-1α) 在心血管衰竭中起着矛盾的作用.
- 双化酶USP22调节HIF-1α的稳定性,但其在CHF中的作用和上游调节尚不清楚.
研究的目的:
- 研究PATZ1/USP22/HIF-1α轴在CHF病变发生过程中的作用和调控机制.
- 阐明PATZ1如何影响USP22和随后的HIF-1α稳定性在CHF的背景下.
主要方法:
- 在体外 (Angiotensin II诱导的H9c2细胞) 和体内 (小鼠腹腔大动脉收缩) 建立的CHF模型.
- 使用了基因操纵 (shRNA,过度表达),细胞活力测试 (CCK-8,TUNEL),心脏功能评估 (血液动力学) 和分子分析 (西斑,Co-IP,无处不在,CHX追逐,ChIP-qPCR,光酶测试).
主要成果:
- 在人体CHF数据集和实验模型中,USP22被升级.
- 通过USP22 Knockdown减少心肌细胞损伤并改善心脏功能,而USP22过度表达会加剧损伤.
- USP22通过二氧化稳定了HIF-1α;HIF-1α过度表达逆转了USP22的淘汰效应.
- PATZ1通过转录激活了USP22,而PATZ1沉默减轻了CHF损伤,这种效应被USP22共同过度表达所废除.
结论:
- PATZ1通过转录上调USP22来促进CHF的进展,USP22通过duebiquitination稳定HIF-1α.
- PATZ1/USP22/HIF-1α轴是CHF病变发生的一个关键途径.
- 针对PATZ1/USP22/HIF-1α轴为CHF提供了一个潜在的治疗策略.
相关概念视频
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895